AnaptysBio may have ended last year on a low, but 2025 is looking up with the news that its PD-1 agonist rosnilimab has ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Its most advanced project is MB272, an agonist of B- and T-lymphocyte attenuator (BTLA) which recently started phase 1 testing, and it has a PD-1 agonist called MB151 in late preclinical development.

Achieved statistical significance on primary endpoint at Week 12 on mean change from baseline DAS-28 CRP across all rosnilimab doses vs.

Analysts have recently evaluated AnaptysBio and provided 12-month price targets. The average target is $36.17, accompanied by ...

AnaptysBio, Inc. (ANAB) shares rallied 30.5% in the last trading session to close at $16.15. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

AnaptysBio (ANAB) announced statistically significant Week 12 data from the global 424-patient Phase 2b RENOIR trial of investigational ...

If you continue to have this issue please contact customerservice@slackinc.com. GLP-1 receptor agonist use before pregnancy was tied to lower risks for hypertensive disorders of pregnancy and ...